Rituximab in ANCA-Associated Vasculitis

被引：43
|
作者：
Hassan, Romina I. [1 ]
Gaffo, Angelo L. [2 ,3 ]
机构：
[1] JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina
[2] Birmingham VA Med Ctr, 700 19th St S, Birmingham, AL 35233 USA
[3] Univ Alabama Birmingham, Div Rheumatol & Clin Immunol, 1825 Univ Blvd,SHEL 306, Birmingham, AL 35294 USA
来源：
CURRENT RHEUMATOLOGY REPORTS | 2017年 / 19卷 / 02期
关键词：
Rituximab; Vasculitis; ANCA; Granulomatosis with polyangiitis (GPA); Microscopic polyangiitis (MPA); Eosinophilicgranulomatosiswith polyangiitis (EGPA); WEGENERS-GRANULOMATOSIS; RANDOMIZED-TRIAL; PLASMA-EXCHANGE; CYCLOPHOSPHAMIDE; INDUCTION; REMISSION; THERAPY; MAINTENANCE; MANAGEMENT; RELAPSES;
D O I：
10.1007/s11926-017-0632-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of Review The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). Recent Findings A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014-2015 online abstracts were also reviewed whether they were RTCs or not. Ten PubMed RCTs were analyzed along with eight ACR and four EULAR abstracts. RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; it was superior to CYC in patients with relapsing disease and superior for remission maintenance in comparison with azathioprine (AZA). Summary Rituximab is a therapeutic option to induce and maintain remission in patients with AAV.
引用
收藏
页数：8
相关论文
共 50 条
  • [31] Severe infections in patients with ANCA-associated vasculitis treated with rituximab
    Segelmark, Leo
    Flores-Suarez, Luis
    Mohammad, Aladdin
    RHEUMATOLOGY, 2022, 61 (01) : 205 - 212
  • [32] Treatment of Severe and/or Refractory ANCA-Associated Vasculitis
    Guillevin, Loic
    CURRENT RHEUMATOLOGY REPORTS, 2014, 16 (08)
  • [33] Treatment of ANCA-Associated Vasculitis, Where to Go?
    Kallenberg, Cees G. M.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2012, 43 (03) : 242 - 248
  • [34] Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
    Treppo, Elena
    Binutti, Marco
    Agarinis, Roberto
    De Vita, Salvatore
    Quartuccio, Luca
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
  • [35] Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
    Guillevin, L.
    Pagnoux, C.
    Karras, A.
    Khouatra, C.
    Aumaitre, O.
    Cohen, P.
    Maurier, F.
    Decaux, O.
    Ninet, J.
    Gobert, P.
    Quemeneur, T.
    Blanchard-Delaunay, C.
    Godmer, P.
    Puechal, X.
    Carron, P. -L.
    Hatron, P. -Y.
    Limal, N.
    Hamidou, M.
    Ducret, M.
    Daugas, E.
    Papo, T.
    Bonnotte, B.
    Mahr, A.
    Ravaud, P.
    Mouthon, L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19) : 1771 - 1780
  • [36] ANCA-associated vasculitis with renal involvement
    Binda, Valentina
    Moroni, Gabriella
    Messa, Piergiorgio
    JOURNAL OF NEPHROLOGY, 2018, 31 (02) : 197 - 208
  • [37] Rituximab in ANCA-Associated Vasculitis: Fad or Fact?
    Fervenza, Fernando C.
    NEPHRON CLINICAL PRACTICE, 2011, 118 (02): : C182 - C188
  • [38] Review article: Progress of treatment in ANCA-associated vasculitis
    Jayne, David
    NEPHROLOGY, 2009, 14 (01) : 42 - 48
  • [39] Should Rituximab Be Used to Prevent Relapse in Patients with ANCA-Associated Vasculitis?
    McAdoo, Stephen P.
    Pusey, Charles D.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (04): : 641 - 644
  • [40] New-generation therapy for ANCA-associated vasculitis
    Jayne, David
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2013, 17 (05) : 694 - 696
12345